| Title | Author(s) | Year | View Count |
 | Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma | Omata, M; Lesmana, LA; Tateishi, R; Chen, PJ; Lin, SM; Yoshida, H; Kudo, M; Lee, JM; Choi, BI; Poon, RTP; Shiina, S; Cheng, AL; Jia, JD; Obi, S; Han, KH; Jafri, W; Chow, P; Lim, SG; Chawla, YK; Budihusodo, U; Gani, RA; Lesmana, CR; Putranto, TA; Liaw, YF; Sarin, SK | 2010 | 58 |
 | Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions | Ahn, SH; Chan, HLY; Chen, PJ; Cheng, J; Goenka, MK; Hou, J; Lim, SG; Omata, M; Piratvisuth, T; Xie, Q; Yim, HJ; Yuen, MF | 2010 | 145 |
| Prevention of hepatocellular carcinoma in hepatitis B virus infection | Lim, SG; Mohammed, R; Yuen, MF; Kao, JH | 2009 | 41 |
| Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial | Chan, HLY; Heathcote, EJ; Marcellin, P; Lai, CL; Cho, M; Moon, YM; Chao, YC; Myers, RP; Minuk, GY; Jeffers, L; Sievert, W; Bzowej, N; Harb, G; Kaiser, R; Qiao, XJ; Brown, NA; Crawford, D; Lim, SG; Chutaputti, A; Poynard, T | 2007 | 138 |
 | Presence of Biopsy-Proven Histologic Damage (Necroinflammation And Fibrosis) is Common Even When ALT is Less Than 2X ULN in Patients With Chronic Hepatitis B (CHB) | Nerrault, N; Kim, WR; Lim, SG; Papatheodoridis, G; Alberti, A; Yuen, RMF; Goodman, ZD; Vaughan, J; Wilber, R; Kreter, B | 2007 | 96 |
| Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response | Lai, CL; Gane, E; Hsu, CW; Chen, YC; Thongsawat, S; Wang, Y; Chen, Y; Naoumov, N; Han, SH; Hwang, SG; Lim, SG; Brown, NA | 2007 | 108 |
| Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications | Zhou, XJ; Lim, SG; Lloyd, DM; Chao, GC; Brown, NA; Lai, CL | 2006 | 237 |
| Maximal Early Hbv Suppression In Nucleoside-treated Hepatitis B Patients Is Associated With Optimal Virologic And Clinical Efficacy At One Year | Lim, SG; Lai, CL; Thongsawat, S; Wang, Y; Chen, Y; Rasenack, J; Naoumov, N; Chao, G; Brown, N | 2006 | 107 |
| Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients | DiBisceglie A, A; Lai, CL; Gane, E; Chen, YC; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Zeuzem, S; Rasenack, J; Bzowej, N; Han, SH; Naoumov, N; Hwang, SG; Lim, SG; Chao, GC; Fielman, BA; Brown, NA; Study Group The GLOBE, | 2006 | 158 |
| Final Results of a Phase I/II Dose Escalation Trial of Valtorcitabine in Patients with Chronic Hepatitis B | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lloyd, D; Pietropalolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 131 |
| Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B. | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lyoyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 114 |
| Practical Difficulties in the Management of Hepatitis B in the Asia-Pacific Region | Mohamed, R; Desmond, P; Suh, DJ; Amarapurkar, D; Gane, E; Guangbi, Y; Hou, JL; Jafri, W; Lai, CL; Lee, CH; Lee, SD; Lim, SG; Guan, R; Phiet, PH; Piratvisuth, T; Sollano, J; Wu, JC | 2004 | 116 |
| Four years of lamivudine treatment in Chinese patients with chronic hepatitis B | Chang, TT; Lai, CL; Chien, RN; Guan, R; Lim, SG; Lee, CM; Ng, KY; Nicholls, GJ; Dent, JC; Leung, NWY | 2004 | 129 |
| A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection | Lai, CL; Lim, SG; Brown, NA; Zhou, XJ; Lloyd, DM; Lee, YM; Yuen, MF; Chao, GC; Myers, MW | 2004 | 116 |
| Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: Results of a phase I/II clinical trial. | Lai, CL; Brown, NA; Yuen, RMF; Wai, CT; Lloyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Lim, SG | 2004 | 173 |
| A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. | Li, SC; Ong, SC; Lim, SG; Yeoh, KG; Kwong, KS; Lee, V; Lee, W; Lau, J; Wong, I; Kung, N; Leung, WT; Chan, HL; Chan, FK; Sung, JJ; Lee, KK | 2004 | 63 |
| Val-LdT: First evidence of efficacy and safety for a new anti-HBV agent | Lim, SG; Lai, CL; Yuen, RMF; Brown, N; Lloyd, D; Myers, M | 2002 | 107 |
| An ongoing phase I/II dose escalation trial in patients with chronic HBV infection (NV-02B-001) | Lai, CL; Lim, SG; Yuen, RMF; Pow, DM; Myers, MW | 2002 | 52 |
| Safety and Antiviral Effects of Val-LdC and LdT in Patients with Chronic Hepatitis B | Lim, SG; Young, DY; Yuen, MF; Myers, M; Lloyd, D; Brown, N; Lai, CL | 2002 | 120 |
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatiits B e antigen seroconversion rate: results after 3 years of therapy | Leung, NW; Lai, CL; Chang, TT; Guan, R; Lee, CM; Ng, KY; Lim, SG; Wu, PC; Dent, JC; Edmundson, S; Condreay, LD; Chien, RN | 2001 | 115 |
|
